Alnylam Advances New Innovations in RNAi Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Alnylam Pharma (ALNY) Announces Presentation of Positive ALN-TTRsc02 Data as ATTR Amyloidosis Treatment
October 14, 2015 7:03 AM EDTAlnylam Pharma (NASDAQ: ALNY) announced today that it presented key pre-clinical data and provided program guidance for ALN-TTRsc02, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis). The new data were presented at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held October 11 14, 2015, in Leiden, Netherlands. In pre-clinical studies, including those in non-human primates (NHPs), ALN-TTRsc02 achieved potent and highly durable knockdown of serum TTR of up to 99% with multi-month durability achieved after just a single dose, supportive of a potentially once quarterly dose regimen. Based on... More
Alnylam (ALNY) Continues to Expand RNAi Capabilities; FBR Affirms at 'Outperform'
October 13, 2015 12:21 PM EDTFBR affirmed its Outperform rating and $180 price target on Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) after the company announced advancement of innovations in RNAi therapeutics with presentation of scientific data on two new platform technologies. First, the company presented data on its Bis-RNAi platform that... More
